Results 201 to 210 of about 267,118 (262)
Fusariosis in Patients With Hematologic Malignancies in the Era of Antifungal Prophylaxis. [PDF]
Vega P +10 more
europepmc +1 more source
This study employs a spouse‐pair cohort design and an idopNetwork model that integrates evolutionary game theory, predator‐prey dynamics, and developmental modularity theory to reconstruct maximally informative microbial interaction networks. This approach reveals how interspecies interactions drive the phenotypic plasticity of the gut microbiota in ...
Huizhen Li +15 more
wiley +1 more source
Editorial: Chimeric antigen receptor T cell therapies and bispecific antibodies in hematologic malignancies. [PDF]
Zhu Y.
europepmc +1 more source
AARS2‐SIRT5‐Driven DLD K445 Lactylation Promotes Cuproptosis Resistance in Glioblastoma Stem Cells
Lactylation of DLD at K445 by AARS2 suppresses PDH complex activity and reduces DLAT lipoylation, thereby conferring cuproptosis resistance in glioblastoma stem cells. SIRT5‐mediated delactylation restores PDH function and enhances cuproptosis sensitivity.
Mingtian Ding +12 more
wiley +1 more source
Outcomes of germ line testing for children with hematologic malignancies undergoing hematopoietic cell transplantation. [PDF]
Pandey AS +19 more
europepmc +1 more source
This review systematically elaborates on the mechanisms underlying physiological regulation and pathological dysregulation of biomolecular phase separation. It also summarizes advances in phase‑separation‑targeted therapeutic strategies and the design of functional biomaterials inspired by this process.
Jiawei Zhu +5 more
wiley +1 more source
Long-term cardiovascular risk in survivors of hematologic malignancies: a meta-analysis. [PDF]
Liu S +5 more
europepmc +1 more source
Mitochondrial localization of Cx26 emerges as a double‐edged sword in colorectal cancer. PIMT‐mediated methylation of Cx26 promotes its mitochondrial localization and stability. Mitochondrial Cx26 then facilitates ER‐mitochondria communication and Ca2+ signaling, thereby promoting metastatic progression. Bortezomib exploits this malignant adaptation by
Jie Wang +9 more
wiley +1 more source

